IC-8 Apthera IOL New Enrollment Post Approval Study

Inclusion Criteria:

• 22 years of age or older, any race and any gender;

• Posterior capsule opacification (PCO) requiring treatment in the IC-8 Apthera IOLeye

• Able to comprehend and have signed a statement of informed consent;

• Availability, willingness, ability and sufficient cognitive awareness to comply withexamination procedures and study visits;

• Clear intraocular media in both eyes;

• Preoperative corneal astigmatism ≤1.5 D in the IC-8 Apthera IOL eye prior to IC-8Apthera implantation;

• Prior IC-8 Apthera IOL implantation in one eye and a monofocal/monofocal toric IOLin the other eye in accordance with the directions for use (DFU) for each IOL.

Exclusion Criteria:

• Pharmacologically dilated pupil size less than 7.0 mm in the IC-8 Apthera IOL eye;

• Irregular astigmatism in either eye;

• History of retinal disease;

• Active or recurrent anterior segment pathology;

• Presence of ocular abnormalities;

• Diagnosis of dry eye in which patients are unable to maintain eye comfort oradequate vision even with dry eye treatment;

• Previous corneal or intraocular surgery, except cataract surgery;

• History of ocular trauma or ocular conditions expected to require retinal lasertreatment or other surgical intervention;

• Acute, chronic or uncontrolled systemic disease that would, in the opinion of theinvestigator, confound the outcomes of the study;

• Patient is pregnant, plans to become pregnant, is lactating or has another conditionassociated with hormonal fluctuation that could lead to refractive changes and dryeye;

• Concurrent participation or participation in any clinical trial up to 30 days priorto the first visit in the study.

• Subjects who plan to be traveling, relocating or otherwise unavailable to attend anyof the visits